Synthon B.v.

Korinde Annemarie Jansen

Farid Abedin Dorkoosh

Frans Van Dalen

Gerrit J B Ettema

Faysal Kalmoua

Raymond J H Westheim

Gerrit Jan Bouke Ettema

Dirk Pamperin

Raymond Jozef Hubertus Westheim

Crystalline aripiprazole Type II can be formulated into pharmaceutical tablets having reduced dissolution profile variability upon storage.

Pharmaceutical tablets of crystalline type II aripiprazole

Low dose pharmaceuticals can be delivered for a prolonged period using a tablet-in-tablet design wherein the drug is contained in a controlled release matrix in the outer compression coating layer but not in the inner tablet core.

Low dose controlled release tablet

A zolpidem tablet having modified release is designed as a tablet-in-tablet dosage form.

Zolpidem tablets

A tamsulosin controlled release tablet is formed using a water-swellable matrix-forming composition as a release controlling mechanism. The matrix forming composition comprises (i) a pH-sensitive swellable hydrophilic polymer, which is a cross-linked polyacrylic acid polymer, and (ii) a pH-insensitive swellable hydrophilic polymer. The tablet optionally contains a water insoluble binder as well.

Tablet composition with a prolonged release of tamsulosin

A pharmaceutical composition comprising (i) quetiapine or a pharmaceutically acceptable salt thereof, especially quetiapine fumarate; (ii) a mixed excipient comprising an intimate admixture of polyvinylacetate and polyvinylpyrrolidone in a weight ratio from 5:2 to 10:2; and, optionally (iii) an acid especially fumaric acid.

Growing community of inventors

Loo, Netherlands

Korinde Annemarie Jansen